1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH

A.R Hansen,S Probst,R.F Tutrone,M.M Osman,E.S Delpassand,L.T Nordquist,B.L Viglianti,J.M Michalski,J-M Beauregard,O.K Oz,K Courtney,J Jensen,W Wu,N Fleshner,O Sartor,K.N Chi,S.T Tagawa

doi:10.1016/j.annonc.2022.07.1886

1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH

A.R Hansen, S Probst + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1886

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 4	License type: publisher-specific-oa

Affiliation: Princess Margaret Cancer Centre, Jewish General Hospital, Saint Louis University Hospital, University of Washington, Tulane University, NewYork–Presbyterian Hospital

#Metastatic Castration Resistant Prostate Cancer #Prostate-specific Membrane Antigen + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Preliminary results of the SPLASH (NCT04647526) lead-in, a phase 3 study evaluating the PSMA targeted radioligand, 177Lu-PNT2002 (also known as 177Lu-PSMA I&T), in PSMA-positive patients with mCRPC who progressed after treatment with androgen receptor axis-targeted therapy (ARAT), are herein presented.

Full Text